What was Vimizim’s launch price in 2014 (annual) at 380,000?
Vimizim (elapegademase-lvlr) is a medicine used for Fabry disease. Your figure (“annual 380,000”) looks like an annual list-price estimate, but the provided information does not include an official “launch price” source, currency, or country/market.
Where does the 380,000 number come from (country, currency, and whether it’s list price)?
“380,000” can refer to different price concepts depending on the source:
- whether it is a US or non-US market amount,
- list price vs. net price after discounts,
- per-year cost based on a modeled regimen vs. the product’s official launch price,
- treatment cost for a typical patient weight/dosing assumptions vs. a standardized calculation.
To confirm whether the 2014 annual price really was 380,000 and for which jurisdiction, I need at least:
- country (e.g., US, UK, Germany, etc.),
- currency (e.g., USD, GBP, EUR),
- whether you mean list price (WAC/official list) or modeled annual therapy cost,
- and the citation/source (a link, document, or table) you’re referencing.
If you share the source, I can verify the exact launch price and context
Send the page/link or the table you got “2014 annual 380,000” from, and I can restate:
- the exact figure,
- the market/currency,
- whether it is list price or annual cost,
- and any notes about dosing assumptions or discounts.